Patent US5604112A successfully refreshed from Google Patents.
US5604112A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for detecting the cardiotoxicity of compounds
Assignee: Lantheus Medical Imaging Inc
•
Filing: 1993-02-26
•
Granted: 1997-02-18
•
Expires: 2013-02-26
Abstract
Abstract The present invention provides methods of testing the cardiotoxicity of compounds and kits useful for the same.
Inventors
- 👤 Paul D. Crane
- 👤 Cesare Orlandi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 22:27
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5008; G01N33/5014; Y; Y10; Y10S; Y10S435/00; Y10S435/968
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
65 words
A method of testing for cardiotoxicity of a compound comprising the steps of: labeling cells having a negative membrane potential with a labeled lipophilic cationic agent; homogenizing the labeled cells to provide a cell homogenate; incubating the cell homogenate with the compound to be tested; obtaining a mitochondrial fraction from the cell homogenate; measuring the amount of labeled lipophilic cationic agent in the mitochondrial fraction.
Claim 2
Independent Claim
65 words
A method of testing for cardiotoxicity of a compound comprising the steps of: labeling cells having a negative membrane potential with a labeled lipophilic cationic agent; homogenizing the labeled cells to provide a cell homogenate; incubating the cell homogenate with the compound to be tested; obtaining a mitochondrial fraction from the cell homogenate; measuring the amount of labeled lipophilic cationic agent in the mitochondrial fraction.
Claim 3
Dependent Claim
24 words
The method of claim 1 wherein the cells are labeled in vivo by intravenous injection of laboratory animals of the labeled lipophilic cationic agent.
Claim 4
Dependent Claim
23 words
The method of claim 1 wherein the cells are labeled in vitro by administration of the labeled lipophilic cationic agent to the cells.
Claim 5
Dependent Claim
15 words
The method of claim 1 wherein the cells are EJ, RT4, SKBR3 or MCF7 cells.
Claim 6
Dependent Claim
46 words
The method of claim 1 wherein the lipophilic cationic agent is labeled with a radiolabel selected from the group consisting of a radioactive isotope of carbon, hydrogen, iodine, technetium, ruthenium, cobalt, platinum, iron, osmium, iridium, tungsten, rhenium, chromium, molybdenum, manganese, nickel, rhodium, lead, niobium, and terbium.
Claim 7
Dependent Claim
27 words
The method of claim 5 wherein the radioactive isotope is selected from the group consisting of C-14, H-3, I-125, Tc-99m, Tc-99, Ru-97, Cr-51, Co-57, Re-188, and Os-191.
Claim 8
Dependent Claim
11 words
The method of claim 6 wherein the radioactive isotope is Tc-99m.
Claim 9
Dependent Claim
17 words
The method of claim 1 wherein the lipophilic cationic agent is labeled with a cationic lipophilic dye.
Claim 10
Dependent Claim
10 words
The method of claim 8 wherein the dye is rhodamine.
Claim 11
Independent Claim
84 words
A method of testing for cardiotoxicity of a compound comprising the steps of: labeling cells having a negative membrane potential with a labeled isonitrile having the formula where M is a label and R is a straight, branched, or cyclic chain C 1 -C 10 alkyl group; homogenizing the labeled cells to provide a cell homogenate; incubating the cell homogenate with the compound to be tested; obtaining a mitochondrial fraction from the cell homogenate; measuring the amount of labeled isonitrile in the mitochondrial fraction.
Claim 12
Independent Claim
84 words
A method of testing for cardiotoxicity of a compound comprising the steps of: labeling cells having a negative membrane potential with a labeled isonitrile having the formula where M is a label and R is a straight, branched, or cyclic chain C 1 -C 10 alkyl group; homogenizing the labeled cells to provide a cell homogenate; incubating the cell homogenate with the compound to be tested; obtaining a mitochondrial fraction from the cell homogenate; measuring the amount of labeled isonitrile in the mitochondrial fraction.
Claim 13
Dependent Claim
19 words
The method of claim 10 wherein the cells are labeled in vivo by intravenous injection of the labeled isonitrile.
Claim 14
Dependent Claim
21 words
The method of claim 10 wherein the cells are labeled in vitro by administration of the labeled isonitrile to the cells.
Claim 15
Dependent Claim
15 words
The method of claim 10 wherein the cells are EJ, RT4, SKBR3 or MCF7 cells.
Claim 16
Dependent Claim
45 words
The method of claim 10 wherein the labeled isonitrile is labeled with a radiolabel selected from the group consisting of a radioactive isotope of carbon, hydrogen, iodine, technetium, ruthenium, cobalt, platinum, iron, osmium, iridium, tungsten, rhenium, chromium, molybdenum, manganese, nickel, rhodium, lead, niobium, and terbium.
Claim 17
Dependent Claim
27 words
The method of claim 14 wherein the radioactive isotope is selected from the group consisting of C-14, H-3, I-125, Tc-99m, Tc-99, Ru-97, Cr-51, Co-57, Re-188, and Os-191.
Claim 18
Dependent Claim
11 words
The method of claim 15 wherein the radioactive isotope is Tc-99m.
Claim 19
Dependent Claim
17 words
The method of claim 10 wherein the lipophilic cationic agent is labeled with a cationic lipophilic dye.
Claim 20
Dependent Claim
10 words
The method of claim 17 wherein the dye is rhodamine.
Claim 21
Independent Claim
149 words
A method of testing for cardiotoxicity of a compound comprising the steps of: labeling cells having a negative membrane potential with a labeled ether-substituted isonitrile having the formula wherein M is a radionuclide, A is a straight or branched chain alkyl group and R is a straight or branched chain alkyl group, provided that the total number of carbon atoms in A plus R is 4 to 6, further provided that when the total number of carbon atoms in A plus R is 6, that the carbon atom alpha to the isonitrile group is a quaternary carbon, and still further provided that A is not (CH 2 ) 3 ; homogenizing labeled cells to provide a cell homogenate; incubating the cell homogenate with the compound to be tested; obtaining a mitochondrial fraction from the cell homogenate; and measuring the amount of labeled ether-substituted isonitrile released from the mitochondrial fraction.
Claim 22
Independent Claim
149 words
A method of testing for cardiotoxicity of a compound comprising the steps of: labeling cells having a negative membrane potential with a labeled ether-substituted isonitrile having the formula wherein M is a radionuclide, A is a straight or branched chain alkyl group and R is a straight or branched chain alkyl group, provided that the total number of carbon atoms in A plus R is 4 to 6, further provided that when the total number of carbon atoms in A plus R is 6, that the carbon atom alpha to the isonitrile group is a quaternary carbon, and still further provided that A is not (CH 2 ) 3 ; homogenizing labeled cells to provide a cell homogenate; incubating the cell homogenate with the compound to be tested; obtaining a mitochondrial fraction from the cell homogenate; and measuring the amount of labeled ether-substituted isonitrile released from the mitochondrial fraction.
Claim 23
Dependent Claim
23 words
The method of claim 19 wherein the cells are labeled in vivo by intravenous injection of laboratory animals of the labeled ether-substituted isonitrile.
Claim 24
Dependent Claim
22 words
The method of claim 19 wherein the cells are labeled in vitro by administration of the labeled ether-substituted isonitrile to the cells.
Claim 25
Dependent Claim
15 words
The method of claim 19 wherein the cells are EJ, RT4, SKBR3 or MCF7 cells.
Claim 26
Dependent Claim
45 words
The method of claim 19 wherein the ether-substituted isonitrile is labeled with a radiolabel selected from the group consisting of a radioactive isotope of carbon, hydrogen, iodine, technetium, ruthenium, cobalt, platinum, iron, osmium, iridium, tungsten, rhenium, chromium, molybdenum, manganese, nickel, rhodium, lead, niobium, and terbium.
Claim 27
Dependent Claim
27 words
The method of claim 23 wherein the radioactive isotope is selected from the group consisting of C-14, H-3, I-125, Tc-99m, Tc-99, Ru-97, Cr-51, Co-57, Re-188, and Os-191.
Claim 28
Dependent Claim
11 words
The method of claim 24 wherein the radioactive isotope is Tc-99m.
Claim 29
Dependent Claim
17 words
The method of claim 19 wherein the lipophilic cationic agent is labeled with a cationic lipophilic dye.
Claim 30
Dependent Claim
10 words
The method of claim 26 wherein the dye is rhodamine.
Claim 31
Dependent Claim
19 words
The method of claim 19 wherein the ether-substituted isonitrile is CNCH 2 C(CH 3 ) 2 OCH 3 .
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-02-18 | 2000-08-19 | 2001-02-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-02-18 | 2004-08-19 | 2005-02-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-02-18 | 2008-08-19 | 2009-02-18 | $7700.00 | Window Closed / Lapsed |